Company Description

Gelteq Limited focuses on developing, testing, and commercializing white label gel-based delivery solutions for humans and animals in Asia-Pacific Region.

It offers edible gels for prescription drugs, nutraceuticals, pet care, and other products, as well as for sports and over-the-counter products.

Gelteq Limited was incorporated in 2017 and is headquartered in Caulfield, Australia.

Gelteq Limited

Country	Australia
Founded	2018
IPO Date	Oct 29, 2024
Industry	Drug Manufacturers - Specialty & Generic
Sector	Healthcare
Employees	8
CEO	Nathan Givoni

Contact Details

Address: 639-641 Glenhuntly Road Caulfield, VIC 3162 Australia
Phone	61 3 9087 3990
Website	gelteq.com

Stock Details

Ticker Symbol	GELS
Exchange	NASDAQ
Fiscal Year	July - June
Reporting Currency	AUD
IPO Price	$4.00
CIK Code	0001920092
ISIN Number	AU0000218109
SIC Code	2834

Key Executives

Name	Position
Nathan Jacob Givoni	Co-Founder, Chief Executive Officer and Executive Director
Simon Hayden Szewach	Co-Founder and Non-Executive Chairman
Thuy-Linh Gigler	Chief Financial Officer
Dr. Paul M. Wynne Ph.D.	Chief Scientific Officer
Adam Bendell	President of U.S. Operations
Matthew Jones	Head of Sports Performance

Latest SEC Filings

Date	Type	Title
Nov 3, 2025	NT 20-F	Notification of inability to timely file Form 20-F
Aug 29, 2025	EFFECT	Notice of Effectiveness
Aug 29, 2025	424B3	Prospectus
Jul 25, 2025	F-1/A	[Amend] Registration statement for certain foreign private issuers
Jul 8, 2025	UPLOAD	Filing
Jul 1, 2025	F-1	Registration statement for certain foreign private issuers
Jun 30, 2025	6-K	Report of foreign issuer
Mar 14, 2025	6-K	Report of foreign issuer
Nov 15, 2024	20-F	Annual and transition report of foreign private issuers
Oct 31, 2024	NT 20-F	Notification of inability to timely file Form 20-F

View All SEC Filings